The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
A New Abuse-Deterrent Opioid - Xtampza ER

The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

ABUSE-DETERRENT OPIOIDS — Five other abuse-deterrent opioid formulations were approved earlier, three as single-drug products and two in combinations with opioid antagonists.1 Two of these products, Morphabond (morphine ER) and Targiniq ER (oxycodone ER/naloxone), have not yet been marketed. Zohydro ER (hydrocodone ER) was reformulated in 2015 to make abuse more difficult, but it has not received FDA approval as an abuse-deterrent opioid. No studies are available comparing the relative safety of these products.

No opioid formulation prevents consumption of a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1497
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian